SCHEMBL473974

SCHEMBL473974

COc1ccc(Cl)c(CC(=O)O)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.68
AKR1C2 P52895 3/20 0.54
PTGS1 P23219 2/20 0.54
AKR1C3 P42330 2/20 0.54
KDM4E B2RXH2 4/20 0.54
TDP1 Q9NUW8 1/20 0.54
CTSD P07339 1/20 0.53
LCK P06239 1/20 0.51
POLB P06746 2/20 0.50
ABL1 P00519 1/20 0.50
MAPT P10636 1/20 0.50
RECQL P46063 1/20 0.50
RIN1 Q13671 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.50
AKR1C4 P17516 1/20 0.49
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
MMP2 P08253 1/20 0.46
MMP8 P22894 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29458589 1.00 HSD17B10 (0.68) HSD17B10AKR1C2PTGS1AKR1C3KDM4E
Hydrochloric Acid SCHEMBL16836023 0.98 HSD17B10 (0.66) HSD17B10AKR1C2PTGS1AKR1C3KDM4E
SCHEMBL473881 0.86 HSD17B10 (0.63) HSD17B10AKR1C2PTGS1AKR1C3KDM4E
SCHEMBL2316645 0.86 HSD17B10 (0.50) HSD17B10AKR1C2PTGS1AKR1C3KDM4E
SCHEMBL16836022 0.86 HSD17B10 (0.50) HSD17B10AKR1C2PTGS1AKR1C3KDM4E
SCHEMBL8040185 0.85 CTSD (0.55) HSD17B10AKR1C2PTGS1AKR1C3TDP1
SCHEMBL474018 0.85 ALDH1A1 (0.52) HSD17B10AKR1C3KDM4ETDP1CTSD
SCHEMBL16267829 0.83 KDM4E (0.52) HSD17B10AKR1C2AKR1C3KDM4EMAPT
SCHEMBL5428835 0.83 POLB (0.65) HSD17B10AKR1C2PTGS1AKR1C3KDM4E
SCHEMBL16267375 0.83 PTGDR (0.59) HSD17B10KDM4EPOLBKMT2AMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066378-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2025-02-27 US disclosed
US-12162887-B2 Spiro-oxazolones HOFFMANN-LA ROCHE INC. (US) 2024-12-10 US disclosed
CN-114984003-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-08-27 CN disclosed
CN-115054600-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-06-14 CN disclosed
EP-3610730-B1 PARASITIC PEST CONTROL AGENT HAVING PYRIDONE COMPOUND AS ACTIVE COMPONENT, AND USE METHOD THEREOF MITSUI CHEMICALS CROP & LIFE SOLUTIONS INC (JP) 2024-01-10 EP disclosed
US-20230106150-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2023-04-06 US disclosed
US-11578077-B2 Spiro-oxazolones HOFFMANN-LA ROCHE INC. (US) 2023-02-14 US disclosed
US-11524938-B2 Aromatic sulfonamide derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-12-13 US disclosed
US-20220324807-A1 AROMATIC SULFONAMIDE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-10-13 US disclosed
CN-115054600-A Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-09-16 CN disclosed
WO-2010108903-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
US-20100249124-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed
EP-2205562-A1 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-07-14 EP disclosed
US-20090088425-A1 GLUCOCORTICOID RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 US disclosed
WO-2009040288-A1 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-04-02 WO disclosed
US-20070093483-A1 Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) ASTRAZENECA AB (SE) 2007-04-26 US disclosed
EP-1620410-A1 USE OF DERIVATIVES OF 2, 4-DIHYDRO- 1,2,4 TRIAZOLE-3-THIONE AS INHIBITORS OF THE ENZYME MYELOPEROXIDASE (MPO) AstraZeneca AB (SE) 2006-02-01 EP disclosed
WO-2004096781-A1 USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO) ASTRAZENECA AB (SE) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324807-A1 AROMATIC SULFONAMIDE DERIVATIVES ARSA, SULT2A1, TPST2 HSD17B10 1659/4885AKR1C2 993/4885PTGS1 2580/4885
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 HSD17B10 223/4885AKR1C2 154/4885PTGS1 347/4885
US-11524938-B2 Aromatic sulfonamide derivatives ARSA, SULT2A1, TPST2 HSD17B10 1659/4885AKR1C2 993/4885PTGS1 2580/4885
US-20100249124-A1 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, MC2R HSD17B10 146/4885AKR1C2 141/4885PTGS1 787/4885
US-12162887-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 HSD17B10 3321/4885AKR1C2 1329/4885PTGS1 1623/4885
US-11578077-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 HSD17B10 3321/4885AKR1C2 1329/4885PTGS1 1623/4885
US-20250066378-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 HSD17B10 3321/4885AKR1C2 1329/4885PTGS1 1623/4885
US-20090088425-A1 GLUCOCORTICOID RECEPTOR ANTAGONISTS NR3C1, NR3C2, MC2R HSD17B10 325/4885AKR1C2 266/4885PTGS1 511/4885
US-20230106150-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 HSD17B10 3321/4885AKR1C2 1329/4885PTGS1 1623/4885
US-20070093483-A1 Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) MPO, XDH, EPX HSD17B10 922/4885AKR1C2 1970/4885PTGS1 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.